AIM Company Profile and Key Details

Q: Who are the executives of AIM?

Dr. Carol A. SmithChief Manufacturing Officer & Deputy Chief Scientific OfficerDr. Christopher McAleer Ph.D.Scientific OfficerDr. David R. Strayer M.D.Chief Scientific Officer & Medical DirectorAnn Marie E. CoverlyDirector of Admin. & HR and Deputy Investor Relations CoordinatorJodie PelzControllerDr. Ralph Christopher Cavalli Ph.D.Vice President of QC & ManufacturingMr. Thomas K. Equels Esq., J.D., M.S.Executive Vice Chairman, Chief Executive Officer & PresMr. Peter W. Rodino III, Esq., J.D.Chief Operating Officer, Executive Director of Gov.al Relations, Gen. Counsel & Sec.

AMEX : AIM

AIM ImmunoTech

$0.60

0.045+8.18%

At Close 4:00 PM

63.57

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

AIM ImmunoTech Inc. (AIM) stock surged +8.18%, trading at $0.60 on AMEX, up from the previous close of $0.55. The stock opened at $0.55, fluctuating between $0.54 and $0.61 in the recent session.

Stock Snapshot

0.55

Prev. Close

2.03M

Market Cap

0.54

Day Low

-0.07

P/E Ratio

-8.62

EPS (TTM)

-0.45

Cash Flow per Share

0.55

Open

3.4M

Number of Shares

0.6099

Day High

95.49%

Free Float in %

0.21

Book Value

192.73K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Apr 02, 2026	0.55	0.61	0.54	0.60	194.3K
Apr 01, 2026	0.60	0.60	0.55	0.55	280.63K
Mar 31, 2026	0.55	0.59	0.54	0.59	208.03K
Mar 30, 2026	0.71	0.73	0.53	0.55	630.84K
Mar 27, 2026	0.74	0.77	0.70	0.70	281.33K
Mar 25, 2026	0.99	0.99	0.84	0.85	860.8K
Mar 24, 2026	0.96	1.05	0.90	0.97	1.03M
Mar 23, 2026	0.93	1.02	0.93	0.96	976.36K
Mar 20, 2026	0.93	1.02	0.87	0.96	1.68M
Mar 19, 2026	0.92	0.95	0.89	0.92	3.92M
Mar 18, 2026	1.45	1.62	0.97	1.02	182.54M
Mar 17, 2026	0.73	0.76	0.69	0.71	61.65K
Mar 16, 2026	0.74	0.77	0.69	0.73	126.04K
Mar 13, 2026	0.70	0.73	0.67	0.73	59.57K
Mar 12, 2026	0.69	0.72	0.66	0.68	260.7K
Mar 11, 2026	0.71	0.72	0.68	0.68	112.35K
Mar 10, 2026	0.73	0.76	0.67	0.70	78.72K
Mar 09, 2026	0.71	0.74	0.66	0.72	97.65K
Mar 06, 2026	0.66	0.78	0.64	0.69	318.36K
Mar 03, 2026	0.78	0.78	0.67	0.70	192.37K

Contact Details

Ocala, FL 34473

United States

https://aimimmuno.com 352 448 7797

About Company

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. Its flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts. The company is also developing Ampligen for potential treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.

Stock Peers

TBXU

Direxion Daily Biotech Top 5 Bull 2X ETF$31.88 PTHS

-0.9-4.23%

Pelthos Therapeutics Inc.$20.40 PTN

0.52+3.02%

Palatin Technologies, Inc.$17.72 AGE

-1.5-11.90%

AgeX Therapeutics, Inc.$11.10 ARMP

-0.38-3.60%

Armata Pharmaceuticals, Inc.$10.18 CYBN

0.1+1.22%

Cybin Inc.$8.28 NRXS

0.07+0.97%

NeurAxis, Inc.$7.25 PHGE

0.36+10.91%

BiomX Inc.$3.66 CVM

0.04+1.17%

CEL-SCI Corporation$3.47 CANF

-0.02-0.65%

Can-Fite BioPharma Ltd.$3.07

Company Overview

AIM ImmunoTech Inc. (AMEX:AIM) closed at $0.59 USD, gaining $0.04 (8.18%) from the previous close of $0.55. The stock is currently mid-range between its 52-week high and low $0.53 and $34.92. With a market capitalization of about $2.03 million, AIM ImmunoTech Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.36). Key stats such as the average daily volume over the past year has been around 4.55 million shares, volume is running light vs its 52-week average. Headquartered in Ocala, FL, AIM ImmunoTech Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Thomas K. Equels, the company employs approximately 21 people and listed since November 02, 1995. AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States.

Technical Performance

Short-term trend indicators are bullishly aligned (SMA20 -8.27%, SMA50 -17.44%, SMA200 -73.02%). The stock’s 14-day RSI is 43.33 (neutral), while the ATR of 0.16 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -97.25% below its high and over 29.36% above its low. Average 10-day trading volume of 409.32 thousand shares is below the 3-month average of 4.65 million, indicating normal recent market interest.

Valuation Metrics

AIM ImmunoTech Inc. trades at a P/E ratio of -0.13, slightly below the S&P 500 average, with a price-to-sales ratio of 23.01 and a price-to-book ratio of -0.19 indicating negative book value, which may reflect financial stress. The P/FCF stands at -0.18, also below market averages.

Dividend & Fair Value

AIM ImmunoTech Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.29. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

AIM ImmunoTech Inc. generated EPS of -$20.14 over the past year. Five-year average earnings growth is 34.59%. The latest quarter delivered EPS of -$0.32. The next quarter is forecast at -$0.94. Next year's EPS is expected at $2.17. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 2 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $24.00 to $24.00. The high target offers 3967.8% upside. The low target suggests 3967.8% downside. The mean target is $24.00. This offers 3967.8% upside. AIM ImmunoTech Inc. earnings surprise history is frequent misses against expectations. The quarter that ended November 17, 2025, missed forecasts by -67.35%. The prior quarter beat by -54.0%. Over the last six quarters, Apple has recorded several small beats. These include -75.0% in August 14, 2024.

Shareholding & Insider Activity

AIM ImmunoTech Inc. has 4.22 million shares outstanding. The public float is 7.99 million shares, elevated short interest at 3.71% of float. This equals 153.26 thousand shares. The short ratio is 0.38 days. Institutional investors hold 5.13% of the float. Insiders own 3.85%. KELLNER TED D holds 1.97 million shares, CARTER WILLIAM A has 1.23 million shares and MITCHELL WILLIAM M has 521.72 thousand shares.

Financial & Profitability Overview

Over the trailing twelve months, AIM ImmunoTech generated $202.00K in revenue, or $0.00 per share. Gross margin was -38.61%, operating margin -15793.07%, and net profit margin -14337.62%. Returns are negative, with ROA at -149.15% and ROE at -283.00%.
On valuation metrics, AIM ImmunoTech trades at a P/E of -0.13, P/S of 23.01 and P/B of -0.19. Liquidity is tight, with a current ratio of 0.53 and quick ratio of 0.53. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -2615.19 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is -0.50, supported by a cash flow-to-debt ratio of -2.24.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, AIM ImmunoTech posted revenue of $202.00K, down slightly from $141.00K in the prior quarter. Gross profit was - $78.00K (margin -38.61%). Operating income was - $31.90M (margin -15793.1%). Net income was- $28.96M (EPS - $0.60).
The company ended the quarter with $13.07M in cash and short-term investments, a total debt of $718.00K, and net debt of - $4.72M. Total assets were $19.42M, with equity of $10.23M. Financials further reflected weakness, with operating cash flow of - $21.27M, free cash flow of - $21.85M, and capital expenditures of - $585.00K.

Price Forecast & Outlook

Our AI price prediction model suggests that AIM ImmunoTech Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -22.69%, with price expected at $0.46 by April 16, 2026, within a range of $0.26 to $0.64 3-Month Outlook: Projected rise of 263.03%, reaching $2.16 by July 01, 2026, with a range of $1.27 to $2.27. 1-Year Outlook: Projected loss of -94.96%, with price at $0.03 by April 02, 2027, within a range of $0.00 to $0.00.

Key Takeaways

AIM ImmunoTech Inc. (AMEX:AIM) shares are flat 4.53% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows AIM ImmunoTech Inc. trading at a premium to the broader market with a P/E of -0.13. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $11.70, suggesting 1866.39% upside. Our AI forecast model points to short-term weakness (-22.69% over two weeks), a medium-term rise (263.03% over three months), and a longer-term loss (-94.96% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current AIM ImmunoTech Inc. (AIM) stock price?

AIM ImmunoTech Inc. (AMEX: AIM) stock price is $0.60 in the last trading session. During the trading session, AIM stock reached the peak price of $0.61 while $0.54 was the lowest point it dropped to. The percentage change in AIM stock occurred in the recent session was 8.18% while the dollar amount for the price change in AIM stock was $0.05.

AIM's industry and sector of operation?

The AMEX listed AIM is part of Biotechnology industry that operates in the broader Healthcare sector. AIM ImmunoTech Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of AIM?

Dr. Carol A. Smith
Chief Manufacturing Officer & Deputy Chief Scientific Officer
Dr. Christopher McAleer Ph.D.
Scientific Officer
Dr. David R. Strayer M.D.
Chief Scientific Officer & Medical Director
Ann Marie E. Coverly
Director of Admin. & HR and Deputy Investor Relations Coordinator
Jodie Pelz
Controller
Dr. Ralph Christopher Cavalli Ph.D.
Vice President of QC & Manufacturing
Mr. Thomas K. Equels Esq., J.D., M.S.
Executive Vice Chairman, Chief Executive Officer & Pres
Mr. Peter W. Rodino III, Esq., J.D.
Chief Operating Officer, Executive Director of Gov.al Relations, Gen. Counsel & Sec.

How AIM did perform over past 52-week?

AIM's closing price is 12.26% higher than its 52-week low of $0.53 where as its distance from 52-week high of $34.92 is -98.3%.

How many employees does AIM have?

Number of AIM employees currently stands at 21.

Link for AIM official website?

Official Website of AIM is: https://aimimmuno.com

How do I contact AIM?

AIM could be contacted at phone 352 448 7797 and can also be accessed through its website. AIM operates from 2117 SW Highway 484, Ocala, FL 34473, United States.

How many shares of AIM are traded daily?

AIM stock volume for the day was 192.73K shares. The average number of AIM shares traded daily for last 3 months was 4.55M.

What is the market cap of AIM currently?

The market value of AIM currently stands at $2.03M with its latest stock price at $0.60 and 3.4M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	21
Beta	1.36
Sales or Revenue	$202.00K
5Y Sales Change%	-0.989%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

AIM Company Profile and Key Details

AIM ImmunoTech

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Dividend & Fair Value

Earnings & Analyst Outlook

Company Overview

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Valuation Metrics

Key Takeaways

Price Forecast & Outlook

Technical Performance